机构：[1]Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong, China深圳市康宁医院深圳市中医院深圳医学信息中心[2]Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong, China深圳市康宁医院深圳市中医院深圳医学信息中心[3]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong, China深圳市康宁医院深圳市中医院深圳医学信息中心[4]Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA.
Diabetes and its renal complications are major medical challenges worldwide. There are no effective drugs currently available for treating diabetes and diabetic kidney disease (DKD), especially in type 1 diabetes (T1D). Evidence has suggested that niclosamide ethanolamine salt (NEN) could improve diabetic symptoms in mice of type 2 diabetes (T2D). However, its role in T1D and DKD has not been studied to date. Here we report that NEN could protect against diabetes in streptozotocin (STZ) induced T1D mice. It increased serum insulin levels, corrected the unbalanced ratio of α-cells to β-cells, and induced islet morphologic changes under diabetic conditions. In addition, NEN could impede the progression of DKD in T1D. Specifically, it reduced urinary albumin levels, NAG, NGAL and TGF-β1 excretion, ameliorated renal hypertrophy, alleviated podocyte dysfunction, and suppressed the renal cortical activation of mTOR/4E-BP1 signaling pathway. Moreover, it is hepatoprotective and does not exhibit heart toxicity. Therefore, these findings open up a completely novel therapy for diabetes and DKD.
基金：
This study was supported by grants from National Natural Science Foundation of China (81202818, 81673794, 81373565), and Sh-enzhen Science and Technology Project (JCYJ-20160330171116798, JCYJ2015040116324-7228).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong, China[4]Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA.[*1]Department of Nephrology, Shenzhen Traditional Chinese Me-dicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Futian District, Shenzhen 518033, Guangdong, China.[*2]Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA.
推荐引用方式(GB/T 7714)：
Han Pengxun,Shao Mumin,Guo Lan,et al.Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.[J].American journal of translational research.2018,10(4):1071-1084.
APA：
Han Pengxun,Shao Mumin,Guo Lan,Wang Wenjing,Song Gaofeng...&Sun Huili.(2018).Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice..American journal of translational research,10,(4)
MLA：
Han Pengxun,et al."Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.".American journal of translational research 10..4(2018):1071-1084
